Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards

ESMO Open

article

R. Danesi¹  S. Fogli¹  S. Indraccolo²  M. Del Re¹  A.P. Dei Tos³  L. Leoncini⁴  L. Antonuzzo⁵  L. Bonanno⁶  V. Guarneri⁶  A. Pierini⁸  G. Amunni⁹  P. Conte⁶ 

[1] Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa;Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS;Department of Medicine, School of Medicine, University of Padua;Department of Medical Biotechnology, Anatomic Pathology Division, University of Siena;Medical Oncology Unit, Careggi University Hospital;Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS;Department of Surgery, Oncology and Gastroenterology, University of Padua;Integrated Access;Institute for the Study

关键词: cancer;    biomarker;    target therapy;    oncogenic drivers;    Molecular Tumor Board;   

DOI  :  10.1016/j.esmoop.2020.100040

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

The therapeutic landscape of cancer is changing rapidly due to the growing number of approved drugs capable of targeting specific genetic alterations. This aspect, together with the development of noninvasive methods for the assessment of somatic mutations in the peripheral blood of patients, generated a growing interest toward a new tumor-agnostic classification system based on ‘predictive' biomarkers. The current review article discusses this emerging alternative approach to the classification of cancer and its implications for the selection of treatments. It is suggested that different types of cancers sharing the same molecular profiles could benefit from the same targeted drugs. Although recent clinical trials have demonstrated that this approach cannot be generalized, there are also specific examples that demonstrate the clinical utility of this alternative vision. In this rapidly evolving scenario, a multidisciplinary approach managed by institutional Molecular Tumor Boards is fundamental to interpret the biological and clinical relevance of genetic alterations and the complexity of their relationship with treatment response.

【 授权许可】

CC BY|CC BY-NC-ND